We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $9.86 · 7 analysts
Stored first · Google News · Yahoo Finance (English)
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview ChartMill
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support Test - Seasonality Effect - dars.gov.et
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support Test - Seasonality Effect dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison Intellectia AI
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.2 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 29. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 17. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 01. 17. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2025. 12. 04. | Guggenheim | — | Downgrade | Buy → Neutral | — | Guggenheim: Buy → Neutral |
| 2025. 10. 02. | Freedom Broker | — | Initiate coverage | — → Buy | — | Freedom Broker: Buy |
| 2025. 09. 04. | Guggenheim | — | Initiate coverage | — → Buy | — | Guggenheim: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.